Investigational drug · Phase 3
SUVN-502
Also called: Masupirdine
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Agitation, Alzheimer's Type Dementia.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SUVN-502"
First trial start
2022
Nov 1, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SUVN-502", any sponsor or status.
Conditions studied
As listed on its trial records.
- Agitation
- Alzheimer's Type Dementia
Approved drugs for the same conditions: Alzheimer's disease · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "SUVN-502" as an intervention, largest first.
- SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a StudyPivotal-lookingCompleted
Suven Life Sciences LimitedIndustry
NCT02580305 · 564 participants · Start Sep 2015 · Primary completion Nov 5, 2019
Drug: SUVN-502; Placebo and 2 more · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Costa Mesa, California · 71 sites in all
- Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypePivotal-lookingActive, not recruiting
Suven Life Sciences LimitedIndustry
NCT05397639 · 375 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 2026
Drug: Masupirdine 50 mg; Masupirdine 100 mg and 1 more · For: Agitation; Alzheimer's Type Dementia
Sites: Anaheim, California; Costa Mesa, California; Encino, California · 44 sites in all
- Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's DiseaseNo longer available
Suven Life Sciences LimitedIndustry
NCT03564964
Drug: SUVN-502 · For: Alzheimer Disease; Dementia; Cognition Disorders
Newest research
PubMed records naming it or its code names, newest first.
- Synthesis and preliminary assessment of fluorescent probes based on the competitive GPCR antagonists vismodegib and masupirdine.
Alexander C, Cheung TL, Kumar CA, et al. · RSC Adv 2026
- Masupirdine, a Selective Serotonin 5ߛHT6 Receptor Antagonist for Alzheimer's Disease.
Toledano-Pinedo M, Iriepa I, Rodríguez-Fernández MM, et al. · ACS Pharmacol Transl Sci 2026
- Network meta-analysis of the efficacy of nine drugs for cognitive function in patients with Alzheimer's disease.
Huang S, Guo Y · J Alzheimers Dis Rep 2026
- Divergent late stage functionalisation of luminescent europium(III) complexes for targeting and imaging applications.
Cheung TL, Alexander C, Li H, et al. · Chem Commun (Camb) 2025
- Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer 's disease: A systematic review and network meta- analysis.
Cao W, Zhu B, Liu Z, et al. · Neuroscience 2025
- A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
Lee D, Clark ED, Antonsdottir IM, et al. · Expert Opin Pharmacother 2023
Also in development for Agitation
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- BMS-986368CC-97489Phase 22 trials
Bristol Myers Squibb · Agitation, Alzheimer Disease, Multiple Sclerosis Spasticity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.